2023 World Conference on Lung Cancer (Posters)-EP13.06. hSSB1 is Elevated and a Potential Target for Therapy in SCLC

Pdf Summary

A study conducted by researchers from Queensland University of Technology in Australia has found that hSSB1, a protein involved in DNA damage repair, is elevated in small cell lung cancer (SCLC). They used RNA expression analysis and protein expression in SCLC cell lines to determine the levels of hSSB1. The results showed that hSSB1 was significantly elevated in SCLC compared to normal cells. They also tested a novel oligonucleotide called DKLS02, which targets hSSB1 protein, and found that it impaired DNA damage repair in cancer cells. Furthermore, the researchers found that DKLS02 inhibited the growth of SCLC cell lines. These findings suggest that targeting hSSB1 with oligonucleotides could be a promising therapeutic approach for treating SCLC. <br /><br />SCLC is a challenging form of lung cancer with limited treatment options. Despite recent advances in diagnosis and treatment, SCLC remains the leading cause of cancer mortality worldwide. The introduction of immunotherapy has only shown modest benefits in the disease. Therefore, finding new therapeutic targets is crucial for improving outcomes in patients with SCLC. <br /><br />hSSB1 is a protein involved in the detection and repair of DNA damage. It has been shown to be elevated in various cancers. In this study, the researchers focused on its role in SCLC. They found that hSSB1 was elevated in both RNA and protein expression in SCLC cell lines compared to normal cells. This suggests that hSSB1 could play a role in the development and progression of SCLC. <br /><br />The researchers also tested DKLS02, an oligonucleotide that targets hSSB1 protein. They found that DKLS02 impaired DNA damage repair in cancer cells, indicating its potential as a therapeutic agent. Additionally, DKLS02 inhibited the growth of SCLC cell lines tested, including both adherent and non-adherent cells. This suggests that targeting hSSB1 with DKLS02 could be an effective treatment for SCLC. <br /><br />Overall, this study provides evidence that hSSB1 is elevated in SCLC and that targeting it with oligonucleotides such as DKLS02 could be a viable therapeutic approach for the disease. Further research and clinical trials are needed to validate these findings and determine the effectiveness of this approach in SCLC patients.

Asset Subtitle

Amila Suraweera

Meta Tag

Speaker Amila Suraweera

Topic SCLC & Neuroendocrine Tumors: Preclinical

Keywords

hSSB1

DNA damage repair

small cell lung cancer

RNA expression analysis

protein expression

SCLC cell lines

oligonucleotide

DKLS02

therapeutic approach

cancer treatment